Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Telix Pharmaceuticals Ltd.

telixpharma.com

Latest From Telix Pharmaceuticals Ltd.

Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun

With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.

Deals Asia Pacific

Deal Watch: PDS And Edge Merge To Progress HPV-Linked Cancer Immunotherapy

Immunotherapy firms Edge and PDS announce planned merger, while Telix advances its prostate cancer strategy by acquiring ANMI. Kyowa Hakko Kirin is signed up to distribute GlaxoSmithKline's Phase III CKD-associated anemia product daprodustat in Japan.

Deals M & A

Tech Transfer Roundup: United Neuroscience Unveils Pair Of Collaborations In CTE, Alzheimer’s

Irish biotech focused on Endobody vaccine candidates partners with Boston U. in CTE and U. of Texas in Alzheimer’s. Lupus Research Alliance affiliate will help Bristol conduct a Phase II trial of Tyk2 inhibitor in lupus.

Deals Research & Development

Start-Up Quarterly Statistics: 2017 Fundraising Ends Better Than It Began

But Q4 was the third sequential quarter with a decrease in financing totals. A review of biopharma start-up dealmaking and financing activity from October through December 2017, based on data from Strategic Transactions.

StartUps and SMEs Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Australia
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Telix Pharmaceuticals Ltd.
  • Senior Management
  • Chris Behrenbruch, CEO
    Douglas Cubbin, CFO
    Michael Wheatcroft, PhD, Dir., R&D
    Andreas Kluge, MD, PhD, CMO
  • Contact Info
  • Telix Pharmaceuticals Ltd.
    55 Flemington Rd.
    Ste. 401
    North Melbourne, 3051
    Australia
Advertisement
Advertisement
UsernamePublicRestriction

Register